Sanofi Introduces Dupixent Prefilled Pen for Anti-Interleukin Drug Delivery
Pharmaceutical company Sanofi recently unveiled its latest release, the Dupixent Prefilled Pen, a pre-filled 200mg formulation of the widely-used anti-interleukin drug, Dupixent (dupilumab). This new dosage form comes after the successful launch of the 300mg option in May.
The Dupixent Prefilled Pen has been specifically designed with patient comfort in mind, particularly for those who experience needle anxiety. Unlike its predecessor, the Dupixent Prefilled Injection which utilized a safety cover, the Prefilled Pen cleverly conceals the needle, ensuring it remains hidden before, during, and after administration.
Moreover, the Dupixent Prefilled Pen simplifies the drug delivery process with a single press injection mechanism. The pen features a viewing window on the side, allowing users to confirm completion of the injection visually, or through a distinct sound signal.
Although the approval requirements for both the Dupixent Prefilled Pen and Prefilled Injection are generally the same, it is important to note that only the Dupixent Prefilled Pen is suitable for treating atopic dermatitis in children aged 6 months or older but less than 2 years of age. Insurance benefit claim conditions remain consistent for both formulations.
Patient or caregiver self-injection is possible following thorough training from healthcare professionals on the subcutaneous injection technique using the Dupixent Prefilled Pen. However, it is highly recommended that adolescents between the ages of 12 and 17 receive the injection from an adult or under adult supervision. Likewise, children aged 2 to 11 should be under the supervision of a guardian during the process.
Speaking about the development of the Dupixent Prefilled Pen, a Sanofi representative stated, “This new formulation offers patients, guardians, and caregivers who require periodic injections the flexibility to choose a more convenient treatment method according to individual preferences.” This advancement brings hope for patients suffering from type 2 inflammatory diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, potentially alleviating the burden associated with injection treatments through the user-friendly Dupixent Prefilled Pen.”
Sanofi announced on the 1st that it has released a pre-filled 200mg formulation of the anti-interleukin drug ‘Dupixent (ingredient name: dupilumab)’ through reimbursement. Sanofi launched a 300mg dosage form in May.
Sanofi explained that the Dupixent Prefilled Pen is a useful product for patients who are afraid of needles, as it hides the needle so that it is not visible during or after administration, unlike the Dupixent Prefilled Injection, which has a cover safety current attached to the needle. .
In addition, the Dupixent Prefilled Pen adds that the drug is injected with just one press, and the completion of the injection can be confirmed through the viewing window on the side of the pen or by sound.
The approval requirements for Dupixent Prefilled Pen are generally the same as for Prefilled Pen, but only Dupixent Prefilled Pen can be used for the indications of atopic dermatitis in children 6 months or older and less than 2 years of age. The insurance benefit claim conditions between the two formulations are the same.
Patients or caregivers can self-inject after receiving training on the subcutaneous injection method using the Dupixent pre-filled pen by the medical staff. However, it is recommended that the adolescent between the ages of 12 and 17 is given by an adult instead or given under the guidance of an adult. Children between the ages of 2 and 11 should be supervised by a guardian.
“The Dupixent Prefilled Pen is a formulation developed so that patients, guardians and carers who require periodic injections can choose the treatment method more conveniently according to the patient’s choice.” Patients with type 2 inflammatory diseases, such as atopic dermatitis, are expected. , asthma, and chronic rhinosinusitis with nasal polyps, which have a high disease burden, can alleviate the burden of injection treatment by more easily and conveniently administering drugs with the Dupixent Prefilled Pen,” he said.
#Sanofi #Launches #Dupixent #Prefilled #Pen #Salary
